{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:10:23Z","timestamp":1789427423819,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013093","name":"Science and Technology Planning Project of Shenzhen Municipality","doi-asserted-by":"publisher","award":["KCXFZ20211020163558024"],"award-info":[{"award-number":["KCXFZ20211020163558024"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To assess the effectiveness and safety of combining\n                    <jats:italic>Saccharomyces boulardii<\/jats:italic>\n                    powder with triple therapy as a primary approach for eradicating\n                    <jats:italic>H. pylori<\/jats:italic>\n                    infection, a total of 144 patients who tested positive for\n                    <jats:italic>H. pylori<\/jats:italic>\n                    and diagnosed with non-ulcer dyspepsia underwent endoscopy at two national centers between June 2017 and March 2019 were included. The patients were categorized into three groups using a subsection randomization method and received initial\n                    <jats:italic>H. pylori<\/jats:italic>\n                    eradication treatments. Microbial composition, eradication rates, symptom alleviation, and adverse reactions were monitored on the 14th and 44th days post-treatment. According to PP analysis showed the eradication rates for the SRAC group was 75%, BRAC was 93.18% and RAC was 65.2%. Group BRAC exhibited a marginally higher eradication rate compared to other groups. However, patients receiving\n                    <jats:italic>Saccharomyces boulardii<\/jats:italic>\n                    treatment exhibited an overall reduction in initial dyspepsia symptoms by the end of the treatment period. When employed as a primary strategy, the combination of\n                    <jats:italic>Saccharomyces boulardii<\/jats:italic>\n                    powder with triple therapy displayed notable efficacy and smaller gastrointestinal side effects in eradicating initial\n                    <jats:italic>H. pylori<\/jats:italic>\n                    infections among non-ulcer dyspepsia patients. Moreover, this approach demonstrated advantages in alleviating symptoms, exhibited favorable tolerance, and maintained a high level of clinical safety.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-63894-z","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T11:02:04Z","timestamp":1717758124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection"],"prefix":"10.1038","volume":"14","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"issue":"16 Suppl 1(0 1)","key":"63894_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-5378.2011.00874.x","volume":"16","author":"KL Goh","year":"2011","unstructured":"Goh, K. L. et al. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 16(16 Suppl 1(0 1)), 1\u20139 (2011).","journal-title":"Helicobacter"},{"issue":"12","key":"63894_CR2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/ajg.2010.324","volume":"105","author":"Z Li","year":"2010","unstructured":"Li, Z. et al. Epidemiology of peptic ulcer disease: Endoscopic results of the systematic investigation of gastrointestinal disease in China. Am. J. Gastroenterol. 105(12), 2570\u20132577 (2010).","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"63894_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jgh.15751","volume":"37","author":"S Ren","year":"2021","unstructured":"Ren, S. et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 37(3), 464\u2013470 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"63894_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/gutjnl-2022-328965","volume":"72","author":"XZ Zhou","year":"2023","unstructured":"Zhou, X. Z. et al. Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: The time to change practice for related disease prevention. Gut 72(5), 855\u2013869 (2023).","journal-title":"Gut"},{"issue":"2","key":"63894_CR5","doi-asserted-by":"publisher","first-page":"e12475","DOI":"10.1111\/hel.12475","volume":"23","author":"WZ Liu","year":"2018","unstructured":"Liu, W. Z. et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 23(2), e12475 (2018).","journal-title":"Helicobacter"},{"issue":"3 Suppl 2","key":"63894_CR6","doi-asserted-by":"publisher","first-page":"812S","DOI":"10.1093\/jn\/137.3.812S","volume":"137","author":"D Lesbros-Pantoflickova","year":"2007","unstructured":"Lesbros-Pantoflickova, D., Corthesy-Theulaz, I. & Blum, A. L. Helicobacter pylori and probiotics. J. Nutr. 137(3 Suppl 2), 812S-S818 (2007).","journal-title":"J. Nutr."},{"issue":"5","key":"63894_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1523-5378.2009.00716.x","volume":"14","author":"J Zou","year":"2009","unstructured":"Zou, J., Dong, J. & Yu, X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 14(5), 97\u2013107 (2009).","journal-title":"Helicobacter"},{"issue":"10","key":"63894_CR8","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1365-2036.2005.02448.x","volume":"21","author":"E Myllyluoma","year":"2005","unstructured":"Myllyluoma, E. et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy\u2013A placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol. Ther. 21(10), 1263\u20131272 (2005).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"Suppl 1","key":"63894_CR9","first-page":"S99","volume":"6","author":"H Zojaji","year":"2013","unstructured":"Zojaji, H. et al. The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H. pylori: A randomized controlled trial. Gastroenterol. Hepatol. Bed Bench 6(Suppl 1), S99\u2013S104 (2013).","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"issue":"1","key":"63894_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5223\/pghn.2015.18.1.17","volume":"18","author":"Z Bin","year":"2015","unstructured":"Bin, Z. et al. The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children. Pediatr. Gastroenterol. Hepatol. Nutr. 18(1), 17\u201322 (2015).","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"issue":"109","key":"63894_CR11","first-page":"1148","volume":"58","author":"K Ozdil","year":"2011","unstructured":"Ozdil, K. et al. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepato Gastroenterol. 58(109), 1148 (2011).","journal-title":"Hepato Gastroenterol."},{"issue":"1","key":"63894_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13568-020-01053-z","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Sulforaphane alter the microbiota and mitigate colitis severity on mice ulcerative colitis induced by DSS. AMB Express 10(1), 119 (2020).","journal-title":"AMB Express"},{"issue":"2","key":"63894_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2016.563","volume":"112","author":"WD Chey","year":"2017","unstructured":"Chey, W. D. et al. ACG clinical guideline: Treatment of Helicobacter pylori Infection. Am. J. Gastroenterol. 112(2), 212\u2013239 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"63894_CR14","doi-asserted-by":"publisher","first-page":"1042070","DOI":"10.3389\/fcimb.2022.1042070","volume":"12","author":"B Liang","year":"2022","unstructured":"Liang, B. et al. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front. Cell. Infect. Microbiol. 12, 1042070 (2022).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"63894_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jgar.2018.03.005","volume":"14","author":"ATB Abadi","year":"2018","unstructured":"Abadi, A. T. B. & Yamaoka, Y. Helicobacter pylori therapy and clinical perspective. J. Glob. Antimicrob. Res. 14, 111\u2013117 (2018).","journal-title":"J. Glob. Antimicrob. Res."},{"issue":"1","key":"63894_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"Fallone, C. A. et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151(1), 51-69 e14 (2016).","journal-title":"Gastroenterology"},{"issue":"1","key":"63894_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner, P. et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report. Gut 66(1), 6\u201330 (2017).","journal-title":"Gut"},{"key":"63894_CR18","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","volume":"71","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner, P. et al. Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report. Gut 71, 1724\u20131762 (2022).","journal-title":"Gut"},{"issue":"5","key":"63894_CR19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","volume":"65","author":"MP Dore","year":"2016","unstructured":"Dore, M. P., Lu, H. & Graham, D. Y. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 65(5), 870\u2013878 (2016).","journal-title":"Gut"},{"issue":"1","key":"63894_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","volume":"157","author":"CA Fallone","year":"2019","unstructured":"Fallone, C. A., Moss, S. F. & Malfertheiner, P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology 157(1), 44\u201353 (2019).","journal-title":"Gastroenterology"},{"issue":"6","key":"63894_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.intimp.2005.02.006","volume":"5","author":"JA Madden","year":"2005","unstructured":"Madden, J. A. et al. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: A double-blind, placebo-controlled pilot study. Int. Immunopharmacol. 5(6), 1091\u20131097 (2005).","journal-title":"Int. Immunopharmacol."},{"key":"63894_CR22","doi-asserted-by":"publisher","first-page":"175628482211477","DOI":"10.1177\/17562848221147763","volume":"16","author":"XJ He","year":"2023","unstructured":"He, X. J. et al. The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: A single-center, prospective randomized-control study. Therap. Adv. Gastroenterol. 16, 17562848221147764 (2023).","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"12","key":"63894_CR23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/apt.13214","volume":"41","author":"H Szajewska","year":"2015","unstructured":"Szajewska, H., Horvath, A. & Kolodziej, M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol. Ther. 41(12), 1237\u20131245 (2015).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"10058","key":"63894_CR24","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(16)31409-X","volume":"388","author":"JM Liou","year":"2016","unstructured":"Liou, J. M. et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 388(10058), 2355\u20132365 (2016).","journal-title":"Lancet"},{"issue":"3","key":"63894_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1523-5378.2010.00758.x","volume":"15","author":"Q Sun","year":"2010","unstructured":"Sun, Q. et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 15(3), 233\u2013238 (2010).","journal-title":"Helicobacter"},{"issue":"3","key":"63894_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3892\/etm.2015.2174","volume":"9","author":"Z Lv","year":"2015","unstructured":"Lv, Z. et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp. Ther. Med. 9(3), 707\u2013716 (2015).","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"63894_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/hel.12270","volume":"21","author":"B Oh","year":"2016","unstructured":"Oh, B. et al. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: Randomized controlled trial. Helicobacter 21(3), 165\u2013174 (2016).","journal-title":"Helicobacter"},{"issue":"4","key":"63894_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.clinre.2017.04.004","volume":"41","author":"F Wang","year":"2017","unstructured":"Wang, F. et al. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin. Res. Hepatol. Gastroenterol. 41(4), 466\u2013475 (2017).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"63894_CR29","doi-asserted-by":"publisher","first-page":"903002","DOI":"10.3389\/fcimb.2022.903002","volume":"12","author":"P Qu","year":"2022","unstructured":"Qu, P. et al. Saccharomyces boulardii allows partial patients to avoid reusing bismuth quadruple for Helicobacter pylori rescue therapy: A single-center randomized controlled study. Front. Cell. Infect. Microbiol. 12, 903002 (2022).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"16","key":"63894_CR30","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1007\/s00253-015-6776-x","volume":"99","author":"ML Palma","year":"2015","unstructured":"Palma, M. L. et al. Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: Is there room for improvement?. Appl. Microbiol. Biotechnol. 99(16), 6563\u20136570 (2015).","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"6","key":"63894_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.01693-15","volume":"6","author":"E Zaura","year":"2015","unstructured":"Zaura, E. et al. Same exposure but two radically different responses to antibiotics: Resilience of the salivary microbiome versus long-term microbial shifts in feces. Mbio 6(6), 10\u20131128 (2015).","journal-title":"Mbio"},{"issue":"2","key":"63894_CR32","doi-asserted-by":"publisher","first-page":"e12870","DOI":"10.1111\/hel.12870","volume":"27","author":"SG Cifuentes","year":"2022","unstructured":"Cifuentes, S. G. et al. Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy. Helicobacter 27(2), e12870 (2022).","journal-title":"Helicobacter"},{"key":"63894_CR33","doi-asserted-by":"publisher","first-page":"101499","DOI":"10.1016\/j.genrep.2022.101499","volume":"26","author":"M Keikha","year":"2022","unstructured":"Keikha, M. & Kamali, H. The impact of Saccharomyces boulardii adjuvant supplementation on alternation of gut microbiota after H. pylori eradication; a metagenomics analysis. Gene Rep. 26, 101499 (2022).","journal-title":"Gene Rep."},{"issue":"1","key":"63894_CR34","doi-asserted-by":"publisher","first-page":"e000182","DOI":"10.1136\/bmjgast-2017-000182","volume":"4","author":"H Yanagi","year":"2017","unstructured":"Yanagi, H. et al. Changes in the gut microbiota composition and the plasma ghrelin level in patients with Helicobacter pylori-infected patients with eradication therapy. BMJ Open Gastroenterol. 4(1), e000182 (2017).","journal-title":"BMJ Open Gastroenterol."},{"key":"63894_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijmedinf.2016.10.020","volume":"97","author":"EW Kluge","year":"2017","unstructured":"Kluge, E. W. Health Information Professionals in a Global eHealth World: Ethical and legal arguments for the international certification and accreditation of health information professionals. Int. J. Med. Inform. 97, 261\u2013265 (2017).","journal-title":"Int. J. Med. Inform."},{"issue":"4","key":"63894_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1128\/CMR.00008-07","volume":"20","author":"HM Wexler","year":"2007","unstructured":"Wexler, H. M. Bacteroides: The good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20(4), 593\u2013621 (2007).","journal-title":"Clin. Microbiol. Rev."},{"issue":"5505","key":"63894_CR37","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1126\/science.291.5505.881","volume":"291","author":"LV Hooper","year":"2001","unstructured":"Hooper, L. V. et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291(5505), 881\u2013884 (2001).","journal-title":"Science"},{"issue":"7","key":"63894_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10096-020-03854-3","volume":"39","author":"PA Cardenas","year":"2020","unstructured":"Cardenas, P. A. et al. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur. J. Clin. Microbiol. Infect. Dis. 39(7), 1365\u20131372 (2020).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63894-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63894-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63894-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T11:07:54Z","timestamp":1717758474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63894-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["63894"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-63894-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3247183\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13152"}}